The filing confirms a deeply loss-making micro-cap pharma transitioning from legacy operations to a focused specialty pharma model. The $26.3M impairment signals that prior acquisition goodwill is impaired, and the $431K revenue base is negligible. Monitor the upcoming Q1 2026 10-Q for ARBLI revenue trajectory and cash burn rate; the company's reliance on equity financing and the Tollo note ($5M principal) for liquidity is a key risk. The correction of immaterial errors and addition of Part III data is administrative, but the underlying financial deterioration is material.
Price Chart
Executive Summary
Scienture Holdings filed Amendment No. 1 to its 2025 10-K to correct immaterial errors in Item 7 (MD&A) and to include Part III information (director/officer details, executive compensation, beneficial ownership, related-party transactions, and auditor fees) that was previously omitted. The filing also reports a net loss from continuing operations of $41.5 million for FY2025, driven by $26.3 million in non-cash impairment charges, versus net income of $9.1 million in FY2024 (which included $27.3 million in discontinued operations income). Revenue grew 216% to $431,609 from initial ARBLI sales, but the company remains deeply unprofitable with an accumulated deficit of $80.6 million.
Key Facts
- Net loss from continuing operations, net of tax, was $41,512,264 for FY2025, compared to a net loss of $18,244,480 in FY2024.
- Revenue was $431,609 in FY2025, up 216% from $136,643 in FY2024, driven by initial ARBLI sales.
- Non-cash impairment charges of $26,346,050 were recognized in FY2025 (goodwill impairment of $21,372,960 and IPR&D impairment of $4,973,090).
- Accumulated deficit as of December 31, 2025 was $80,551,237.
- Cash and cash equivalents were $6,662,008 as of December 31, 2025, with positive working capital of approximately $5,181,000.
- The company raised approximately $26.3 million in gross equity proceeds during FY2025 through its ELOC and other equity transactions.
- No going concern doubt was expressed by management for the next twelve months.
- The amendment corrected immaterial errors in Item 7 and added previously omitted Part III information.
Financial Impact
Net loss from continuing operations of $41.5 million in FY2025, driven by $26.3 million in non-cash impairment charges. Revenue of $431,609 is minimal relative to the $15M market cap.
Risk Factors
- Continued operating losses and reliance on equity/debt financing for liquidity.
- Minimal revenue base ($431K) relative to operating expenses ($16.6M excluding impairments).
- Accumulated deficit of $80.6 million with no clear path to profitability.
- Potential need for further dilutive equity offerings.
- Risk of Nasdaq delisting if market cap or bid price requirements are not met.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 10-K/A Filing (Primary) | 0001493152-26-020707 |
| Document: 0001493152-26-020707-index-headers.html | 0001493152-26-020707 |
| Document: 0001493152-26-020707-index.html | 0001493152-26-020707 |
| Document: 0001493152-26-020707.txt | 0001493152-26-020707 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | Press Release | $2.77 | awaiting T+5 | — | $2.93 (+5.78%) |
Oct 19, 2026 8d ago | 8-K | $3.05 $3.23 | ▲ +5.90% | ▲ +5.82% | $2.93 (−3.93%) |
Oct 13, 2026 14d ago | Press Release | $3.24 $3.05 | ▲ +5.86% | ▲ +4.71% | $2.93 (+9.57%) |
Oct 7, 2026 20d ago | 8-K | $3.86 $3.38 | ▼ −12.44% | ▼ −12.16% | $2.93 (−24.09%) |
May 29, 2026 21w ago | 8-K | $0.3960 $0.3600 | ▼ −9.09% | ▼ −6.34% | $2.93 (+639.90%) |
May 22, 2026 22w ago | 8-K | $0.4000 $0.3910 | ▼ −2.25% | ▼ −3.46% | $2.93 (+632.50%) |
May 18, 2026 23w ago | Press Release | $0.3940 $0.4000 | ▲ +1.52% | ▼ −0.10% | $2.93 (+643.65%) |
May 5, 2026 25w ago | 8-K | $0.3910 $0.3980 | ▲ +1.79% | ▲ +0.66% | $2.93 (+649.36%) |
Apr 30, 2026 25w ago | 10-K/A | $0.4010 $0.4000 | ▲ +0.25% | ▲ +2.60% | $2.93 (−630.67%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers